

Comparison of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for treatment of uncomplicated malaria in Uganda: evaluation of efficacy, safety, and tolerability

Submission date 06/07/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 17/08/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 25/10/2022	Condition category Infections and Infestations	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

<http://www.muucsf.org/>

Contact information

Type(s)

Scientific

Contact name

Dr Grant Dorsey

Contact details

University of California, San Francisco (UCSF)
Box 0811
San Francisco
United States of America
CA 94143
+1 415 206 8687
gdorsey@medsfgh.ucsf.edu

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Version 1.1

Study information

Scientific Title

Comparison of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for treatment of uncomplicated malaria in Uganda: evaluation of efficacy, safety, and tolerability

Acronym

AL vs DP efficacy and safety trial

Study objectives

To compare the efficacy, safety, and tolerability of Artemether-Lumefantrine (AL) and Dihydroartemisinin-Piperaquine (DP) for the treatment of uncomplicated falciparum malaria in Uganda.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. Ugandan National Council of Science and Technology (HS 112; February 14 2006)
2. University of California San Francisco Committee for Human Research (H9926-28076-01; January 11 2006)
3. Makerere University Faculty of Medicine Research and Ethics Committee (January 31 2006).

Study design

Randomised, single-blinded trial of two leading new antimalarial regimens at three sites with varying transmission intensity.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Malaria (P.falciparum)

Interventions

Subjects will be randomised to treatment with AL or DP. Subjects in the DP arm will also receive placebo tablets to ensure that the number of doses received is identical in the two treatment groups.

Subjects who fail initial therapy will receive quinine, the standard treatment for recurrent malaria in Uganda.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Artemether-lumefantrine and dihydroartemisinin-piperaquine

Primary outcome measure

Risk of treatment failure unadjusted and adjusted by genotyping at day 42

Secondary outcome measures

1. Prevalence of fever on days one to three
2. Prevalence of parasitemia on days two and three
3. Change in mean hemoglobin level between days zero and 42 (or day of treatment failure)
4. Prevalence of gametocytes during follow-up
5. Risk of serious adverse events during follow-up
6. Risk of adverse events of moderate or greater severity, at least possibly related to the study medications, excluding patients requiring quinine therapy
7. Selection of molecular markers associated with drug resistance

Overall study start date

20/03/2006

Completion date

20/07/2006

Eligibility**Key inclusion criteria**

1. Aged six months to ten years
2. Weight more than 5 kg
3. Fever (more than 37.5°C axillary) or history of fever in the previous 24 hours
4. Provision of informed consent and agreement to follow-up for 42 days
5. Plasmodium falciparum mono-infection
6. Parasite density more than 2000/μl and less than 200,000/μl

Participant type(s)

Patient

Age group

Child

Lower age limit

6 Months

Upper age limit

10 Years

Sex

Both

Target number of participants

400

Key exclusion criteria

1. Previously enrolled in this study
2. History of serious side effects to study medications
3. Evidence of a concomitant febrile illness
4. Evidence of severe malaria or danger signs
5. Repeated vomiting of study medications on day zero

Date of first enrolment

20/03/2006

Date of final enrolment

20/07/2006

Locations**Countries of recruitment**

Uganda

United States of America

Study participating centre

University of California, San Francisco (UCSF)

San Francisco

United States of America

CA 94143

Sponsor information**Organisation**

Uganda Malaria Surveillance Project (Uganda)

Sponsor details

Mulago Hospital Complex
P.O.Box 7475
Kampala
Uganda
-
+256 41 530 692
info@muucsf.org

Sponsor type
Government

Website
<http://www.muucsf.org>

Funder(s)

Funder type
Government

Funder Name
Centers for Disease Control and Prevention/Global Malaria Prevention and Control Cooperative agreement number U50/CCU925112-01

Funder Name
Department for International Development (DFID) through Malaria Consortium (SUBK0001)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan
Not provided at time of registration

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Other publications		18/05/2007		Yes	No
Results article		11/06/2008		Yes	No